Key Documents
George A. Fisher Jr.
- Associate Professor - Med Center Line, Medicine - Oncology
- Member, Cancer Center
Contact Information
- Clinical Offices
GI Oncology Clinic 875 Blake Wilbur Dr Clinic B Stanford, CA 94305-5820 Telephone Work (650) 498-6000 Fax (650) 725-9113
- Academic Offices
Personal Information Tel (650) 725-9057Administrative Contact Diane Ayala Administrative Assistant Email dayala1@stanford.edu Tel Work 650-725-9057
Administrative Appointments
- Director, Cancer Clinical Trials Office , (2004– present )
Professional Education
- BS, Stanford University Biology (1976)
- PhD, Stanford University Cancer Biology (1987)
- MD, Stanford University Medicine (1987)
- Residency, Stanford University Internal Medicine (1989)
- Fellowship, Stanford University Medical Oncology (1993)
Research Interests
The research program focuses on clinical trials involving new investigational agents for the treatment of a wide range of cancers. Active clinical trials include studies involving doxorubicin and taxol and agents that reverse resistance to these drugs, such as PSC 833.
Other interests include phase I and II studies using anti-sense DNA, targeting PKC-alpha in ovarian cancer and the role of gene-modified autologous T cells engineered to recognize the TAG-72 antigen on colon cancer cells.
Clinical Trials
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Recruiting
- Clinical and Pathologic Studies of Patients Undergoing Treatment with EGFR Inhibitors Recruiting
- Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma Recruiting
- Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors Recruiting
- Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients Recruiting
- A Phase 1/2 Study of Aflibercept Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Carcinoma Recruiting
- A Phase II Study of GSK1363089 (Formerly XL880) for Metastatic Gastric Cancer Recruiting
- A Study of ASA404 or Placebo in Combination With Docetaxel in Second-Line Treatment for (Stage IIIb/IV) Non-Small Cell Lung Cancer (ATTRACT-2) Recruiting
- A Study of XL184 With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer Recruiting
- An Observational Study of the Ethnic Impact of Patients Undergoing 2nd Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed Recruiting
- Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer Recruiting
- Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project Recruiting
- Molecular Genetic and Pathological Studies of Anal Tumors Recruiting
- Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy Recruiting
- Permission to Collect Blood over Time for Research Recruiting
- Ph I Dose-Escalation of AEG40826-2HCI for Advanced Solid Tumors Recruiting
- Ph III Randomized Study of Four Weeks of High-Dose IFN-á2b for Microscopic Melanoma Recruiting
- Phase 1 Trial of Oral Ixabepilone Recruiting
- Phase I Vandetanib plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer Recruiting
- Study of XL518 in Adults With Solid Tumors Recruiting
- Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer Completed
- Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer No longer recruiting
- Safety Study of Cetuximab in combination with Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer Completed
- A Phase I/II Study of HKI-272 in Combination With Paclitaxel in Subjects With Advanced Solid Tumors and Breast Cancer No longer recruiting
- Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer Completed
- Evaluation of Stereotactic Radiosurgery For Liver Malignancies Completed
- Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx Completed
- Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Suspended
- Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer No longer recruiting
- Study of XL647 Administered Orally Daily to Patients With Solid Tumors No longer recruiting
- Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib No longer recruiting
- Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer Completed
Publications
- Cancer. 2009; (3): 665-72
- Dis Esophagus. 2009;
- Proc Natl Acad Sci U S A. 2009; (22): 9010-5
- Ann Oncol. 2009;
- Colorectal Dis. 2009;
- Int J Radiat Oncol Biol Phys. 2008; (3): 678-86
- Clin Oncol (R Coll Radiol). 2008; (1): 69-75
- Am J Clin Oncol. 2008; (1): 84-8
- Clin Cancer Res. 2008; (21): 7074-9
- Ann Oncol. 2008; (9): 1613-8
- J Natl Compr Canc Netw. 2007; S1-29; quiz S30
- Expert Opin Investig Drugs. 2007; (4): 467-76
- Invest New Drugs. 2006; (2): 117-23
- Cancer Biother Radiopharm. 2006; (3): 243-56
- Cancer. 2005; (1): 119-25
- Invest New Drugs. 2005; (3): 241-2
- Int J Radiat Oncol Biol Phys. 2005; (2): 320-3
- Clin Colorectal Cancer. 2005; S62-70
- Ann Oncol. 2005; (12): 1968-73
- Invest New Drugs. 2005; (5): 467-77
- J Clin Oncol. 2005; (24): 5613-9
- Int J Radiat Oncol Biol Phys. 2004; (4): 1017-21
- Cancer. 2004; (2): 321-6
- Clin Cancer Res. 2003; (14): 5187-94
- Int J Radiat Oncol Biol Phys. 2003; (1): 132-7
- J Gastrointest Surg. 2001 Jan-Feb; (1): 27-35
- Transplant Proc. 2001 Feb-Mar; (1-2): 1490-1
- Clin Cancer Res. 2001; (5): 1221-9
- Proc Natl Acad Sci U S A. 2001; (15): 8809-14
- Dis Colon Rectum. 2001; (1): 52-8
- Am J Clin Oncol. 2001; (2): 155-9
- Arch Surg. 2001; (1): 65-9
- Int J Radiat Oncol Biol Phys. 2000; (5): 1483-7
- Cancer Chemother Pharmacol. 2000; (4): 305-11
- Int J Radiat Oncol Biol Phys. 2000; (4): 919-22
- Clin Cancer Res. 1999; (11): 3357-63
- Int J Radiat Oncol Biol Phys. 1998; (1): 93-9
- Cancer Chemother Pharmacol. 1997; S13-9
- Eur J Cancer. 1996; (6): 1082-8
- Hematol Oncol Clin North Am. 1995; (2): 363-82
- Hematol Oncol Clin North Am. 1995; (2): xi-xii
- Cancer Treat Res. 1995; 45-70
- Int J Hyperthermia. 1994 May-Jun; (3): 361-70
- Cancer Treat Res. 1994; 149-65
- J Clin Oncol. 1994; (4): 835-42
- Cancer. 1993; (11 Suppl): 3502-14
- J Clin Oncol. 1992; (10): 1624-34
- Int J Radiat Biol. 1988; (2): 285-98
- Radiat Res. 1987; (2): 351-64